Guidelines for quantifying iron overload

Hematology (United States)

Volumn 2014, Issue 1, 2014, Pages 210-215

  Wood, John C ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FERRITIN; IRON;

BLOOD; HUMAN; IRON OVERLOAD; LIVER; METABOLISM; PRACTICE GUIDELINE;

BIOLOGICAL MARKERS; FERRITINS; HUMANS; IRON; IRON OVERLOAD; LIVER; PRACTICE GUIDELINES AS TOPIC;

EID: 84937574998     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2014.1.210     Document Type: Article

References (42)

1. McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci. 1983;19(3):205-266.
2. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2∗ cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008; 10(1):42.
3. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327-331.
4. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008; 111(2):583-587.
5. Puliyel M, Sposto R, Berdoukas VA, et al. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol. 2014;89(4):391-394.
6. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica. 2011;96(11):1605-1612.
7. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med. 1974;290(22):1213-1216.
8. Chapman RW, Hussain MA, Gorman A, et al. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with betathalassaemia major and iron overload. J Clin Pathol. 1982;35(5):487-491.
9. Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84(1):29-33.
10. Jacobs EM, Hendriks JC, van Tits BL, et al. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal Biochem. 2005;341(2):241-250.
11. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277-287.
12. Wood JC, Glynos T, Thompson A, et al. Relationship between LPI, LIC, and cardiac response in a deferasirox monotherapy trial. Haematologica. 2011;96(7):1055-1058.
13. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632-4639.
14. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-543.
15. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
16. Villeneuve JP, Bilodeau M, Lepage R, Cote J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol. 1996;25(2):172-177.
17. Nielsen P, Engelhardt R, Duerken M, Janka GE, Fischer R. Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. Transfus Sci. 2000;23(3):257-258.
18. Wood JC, Mo A, Gera A, Koh M, Coates T, Gilsanz V. Quantitative computed tomography assessment of transfusional iron overload. Br J Haematol. 2011;153(6):780-785.
19. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusiondependent thalassemia and sickle cell disease patients. Blood. 2005; 106(4):1460-1465.
20. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861.
21. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179.
22. Wood JC, Tyszka JM, Ghugre N, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. Blood. 2004;103(5):1934-1936.
23. Ghugre NR, Wood JC. Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med. 2011;65(3):837-847.
24. Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld E. R2 and R2∗ are equally effective in evaluating chronic response to iron chelation. Am J Hematol. 2014;89(5):505-508.
25. Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld E. Liver MRI is better than biopsy for assessing total boday iron balance: validation by simulation [abstract]. Blood (ASH Annual Meeting Abstracts). 2013; 122(21):958.
26. Storey P, Thompson AA, Carqueville CL, Wood JC, de Freitas RA, Rigsby CK. R2∗ imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging. 2007;25(3):540-547.
27. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca(2 ) channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9(9):1187-1194.
28. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7): 2973-2978.
29. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2∗, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112(4):535-543.
30. Carpenter JP, He T, Kirk P, et al. On T2∗ magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519-1528.
31. Kirk P, Roughton M, Porter JB, et al. Cardiac T2∗ magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
32. Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128(3):281-308.
33. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008;22(Suppl 2):S14-S21.
34. Berdoukas V, Nord A, Carson S, et al. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. Am J Hematol. 2013;88(11):E283-E285.
35. Meloni A, Puliyel M, Pepe A, Berdoukas V, Coates TD, Wood JC. Cardiac iron overload in sickle-cell disease. Am J Hematol. 2014;89(7): 678-683.
36. Fragasso A, Ciancio A, Mannarella C, et al. Myocardial iron overload assessed by magnetic resonance imaging (MRI)T2∗ in multi-transfused patients with thalassemia and acquired anemias. Eur J Intern Med. 2011;22(1):62-65.
37. Noetzli LJ, Panigrahy A, Hyderi A, Dongelyan A, Coates TD, Wood JC. Pituitary iron and volume imaging in healthy controls. AJNR Am J Neuroradiol. 2012;33(2):259-265.
38. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009;114(19): 4021-4026.
39. Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol. 2012;87(2):155-160.
40. Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol. 2009;146(5):546-556.
41. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol. 2012;87(2):167-171.
42. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466-475.